Mechanisms by which cancer cells overcome oncogene addiction in the context of GFR inhibition have undergone extensive investigations [[41], [42], [43], [44]] and it is well-recognized that redundant GFRs can undermine inhibition strategies [[45], [46], [47], [48]]. The gene discussed is RAPGEF5; the disease is cancer.